Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery

This study evaluates the clinical prognostic impact (on DFS and OS) of liquid biopsy guided treatment vs. standard of care (physicians choice) in localized pancreatic cancer (despite because of CA 19-9 levels and computed tomography, upfront surgery is recommended by tumor board). ctDNA positive patients will receive neoadjvuant chemotherapy at current gold standard physicians choice instead of upfront surgery, because of assumed high biological risk for early recurrence.

Trial Details

NCT ID

NCT06391892

Phase

PHASE3

Sponsor

Elisabethinen Hospital

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

• Neoadjuvant chemotherapy instead of upfront surgery
• Upfront surgery

Locations (sample)

• Linz, Upper Austria, Austria|48.30639,14.28611

Key Eligibility Criteria

• Informed consent
• \>18 years old
• localized pancreatic cancer to go for upfront surgery

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →